IPP Bureau
AstraZeneca’s Phase III FLAURA2 trial shows positive result
By IPP Bureau - September 15, 2025
Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
Zhimeng Biopharma’s investigational drug approved to begin phase 2 epilepsy clinical trial in China
By IPP Bureau - September 15, 2025
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Yatharth Hospitals acquires Shantived Hospital in Agra for Rs. 260 Cr
By IPP Bureau - September 14, 2025
Shantived Hospital generated revenue of around Rs 50 crore in FY2025
Briefs: Alembic Pharmaceuticals and Tyche Industries
By IPP Bureau - September 14, 2025
Alembic receives EIR from USFDA for facility at Panelav
Fermenta granted process patent for plant-based Vitamin D3
By IPP Bureau - September 14, 2025
Takeda appoints Rhonda Pacheco President of US Business Unit
By IPP Bureau - September 13, 2025
Rhonda Pacheco to succeed Julie Kim, who was appointed to be Takeda’s next CEO
Biocon Foundation constructs new high school building in Karnataka
By IPP Bureau - September 13, 2025
Biocon Foundation is also expanding its reach with this first initiative in Channapatna region
Apollo Hospitals acquires IFC’s 3% share in Apollo Health and Lifestyle for Rs. 1,254 Cr
By IPP Bureau - September 13, 2025
AHLL will become a 100% subsidiary of AHEL with 99.42% held by AHEL and balance in the ESOP pool
Biocon inaugurates first US manufacturing facility in New Jersey
By IPP Bureau - September 12, 2025
Aarti Drugs receives order from MPCB for closure of process at Tarapur unit
By IPP Bureau - September 12, 2025
The HCl gas is generated continuously which is absorbed in the water scrubber using a chilled falling film system
Shukra Pharmaceuticals inks distribution tie-up with Wockhardt
By IPP Bureau - September 12, 2025
The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin)
NATCO Pharma updates on acquisition of Adcock Ingram
By IPP Bureau - September 12, 2025
VedaBio to use Mammoth Biosciences’ CRISPR-based technology for diagnostic applications
By IPP Bureau - September 12, 2025
CRISPR-based detection enables highly specific molecular recognition
Kytopen collaborates with BlueWhale Bio for cell therapy manufacturing
By IPP Bureau - September 12, 2025
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
iRegene Therapeutics secures series B+ financing
By IPP Bureau - September 12, 2025
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
